Rational design of novel HIV-1 entry inhibitors by RANTES engineering

Luca Vangelista, Massimiliano Secchi, Paolo Lusso

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The discovery that the CC chemokines RANTES, MIP-1α and MIP-1β act as potent natural inhibitors of HIV-1, the causative agent of AIDS, and the subsequent identification of CCR5 as a major virus coreceptor have triggered a wealth of basic and applied research approaches aimed at developing safe and effective viral entry inhibitors. Some of these efforts have focused on RANTES engineering with the goal of enhancing the antiviral activity of the native molecule while reducing or abrogating its inflammatory properties. The wavefront generated a decade ago is still on its course, with a flow of promising leads constantly emerging and being evaluated in preclinical studies. Here, we present an overview of this rapidly evolving field, highlighting the most important features of RANTES molecular architecture and structure-function relationships.

Original languageEnglish
Pages (from-to)3008-3015
Number of pages8
JournalVaccine
Volume26
Issue number24
DOIs
Publication statusPublished - Jun 6 2008
Externally publishedYes

Fingerprint

HIV Fusion Inhibitors
Chemokine CCL5
Human immunodeficiency virus 1
HIV-1
engineering
CC Chemokines
structure-activity relationships
Molecular Structure
Antiviral Agents
Acquired Immunodeficiency Syndrome
Viruses
viruses
Research
chemokine CCL5

Keywords

  • CCR5
  • Chemokine receptors
  • Chemokines
  • HIV-1
  • Inhibitors
  • RANTES
  • Rational design

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Rational design of novel HIV-1 entry inhibitors by RANTES engineering. / Vangelista, Luca; Secchi, Massimiliano; Lusso, Paolo.

In: Vaccine, Vol. 26, No. 24, 06.06.2008, p. 3008-3015.

Research output: Contribution to journalArticle

Vangelista, Luca ; Secchi, Massimiliano ; Lusso, Paolo. / Rational design of novel HIV-1 entry inhibitors by RANTES engineering. In: Vaccine. 2008 ; Vol. 26, No. 24. pp. 3008-3015.
@article{eae10dfaa0f84cb1acc1541d52d3b455,
title = "Rational design of novel HIV-1 entry inhibitors by RANTES engineering",
abstract = "The discovery that the CC chemokines RANTES, MIP-1α and MIP-1β act as potent natural inhibitors of HIV-1, the causative agent of AIDS, and the subsequent identification of CCR5 as a major virus coreceptor have triggered a wealth of basic and applied research approaches aimed at developing safe and effective viral entry inhibitors. Some of these efforts have focused on RANTES engineering with the goal of enhancing the antiviral activity of the native molecule while reducing or abrogating its inflammatory properties. The wavefront generated a decade ago is still on its course, with a flow of promising leads constantly emerging and being evaluated in preclinical studies. Here, we present an overview of this rapidly evolving field, highlighting the most important features of RANTES molecular architecture and structure-function relationships.",
keywords = "CCR5, Chemokine receptors, Chemokines, HIV-1, Inhibitors, RANTES, Rational design",
author = "Luca Vangelista and Massimiliano Secchi and Paolo Lusso",
year = "2008",
month = "6",
day = "6",
doi = "10.1016/j.vaccine.2007.12.023",
language = "English",
volume = "26",
pages = "3008--3015",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "24",

}

TY - JOUR

T1 - Rational design of novel HIV-1 entry inhibitors by RANTES engineering

AU - Vangelista, Luca

AU - Secchi, Massimiliano

AU - Lusso, Paolo

PY - 2008/6/6

Y1 - 2008/6/6

N2 - The discovery that the CC chemokines RANTES, MIP-1α and MIP-1β act as potent natural inhibitors of HIV-1, the causative agent of AIDS, and the subsequent identification of CCR5 as a major virus coreceptor have triggered a wealth of basic and applied research approaches aimed at developing safe and effective viral entry inhibitors. Some of these efforts have focused on RANTES engineering with the goal of enhancing the antiviral activity of the native molecule while reducing or abrogating its inflammatory properties. The wavefront generated a decade ago is still on its course, with a flow of promising leads constantly emerging and being evaluated in preclinical studies. Here, we present an overview of this rapidly evolving field, highlighting the most important features of RANTES molecular architecture and structure-function relationships.

AB - The discovery that the CC chemokines RANTES, MIP-1α and MIP-1β act as potent natural inhibitors of HIV-1, the causative agent of AIDS, and the subsequent identification of CCR5 as a major virus coreceptor have triggered a wealth of basic and applied research approaches aimed at developing safe and effective viral entry inhibitors. Some of these efforts have focused on RANTES engineering with the goal of enhancing the antiviral activity of the native molecule while reducing or abrogating its inflammatory properties. The wavefront generated a decade ago is still on its course, with a flow of promising leads constantly emerging and being evaluated in preclinical studies. Here, we present an overview of this rapidly evolving field, highlighting the most important features of RANTES molecular architecture and structure-function relationships.

KW - CCR5

KW - Chemokine receptors

KW - Chemokines

KW - HIV-1

KW - Inhibitors

KW - RANTES

KW - Rational design

UR - http://www.scopus.com/inward/record.url?scp=44649200690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649200690&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.12.023

DO - 10.1016/j.vaccine.2007.12.023

M3 - Article

VL - 26

SP - 3008

EP - 3015

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 24

ER -